Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2013

View Archived Issues

Boehringer Ingelheim patents new CCR2 receptor antagonists

Scientists elucidate factors necessary for platelet killing of P. falciparum

Takeda provides overview of activities from April-December 2012

Immune responses analyzed in infants administered an enterovirus vaccine

Bristol-Myers Squibb patents new Y4 receptor agonists

New PI3Kgamma and delta inhibitors disclosed by Infinity Pharmaceuticals and Intellikine

Scientists at Theracrine patent novel agents for cancer

Laboratorios del Dr. Esteve synthesizes novel sigma1-receptor ligands

Nanjing Molecular Research divulges new agents for HCV infection

GlaxoSmithKline: fourth quarter 2012 in review

First-in-human results of LNP-encapsulated siRNA therapy show promise in cancer patients

Albany Molecular Research out-licenses tubulin inhibitor

Champions Oncology receives on-time payment under Teva technology collaboration

TG Therapeutics opens expansion cohorts in trial of ublituximab

Catabasis Pharmaceuticals reports phase I data for CAT-1004

Synageva BioPharma begins phase III ARISE trial

UCB and Amgen decide not to pursue romosozumab program in fracture healing

Galenica provides update on regulatory processes for PA-21

Pediatric indication of Ixiaro approved in Europe

French group synthesizes new imino-sugar derivatives

Pfizer presents new GPR119 receptor agonists

Merck KGaA synthesizes novel FSH receptor agonists

Revlimid approved in China, gets priority review for new indication in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...